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Abstract: Rats were trained for multiple sessions in a place-conditioning shuttle-box to 
explore motivational interactions of mu and kappa opioid agonists, specifically fentanyl 
reward and spiradoline aversion. In Phase 1, groups of rats received various doses of mu or 
kappa agonists, or placebo, testing for preference or aversion. Group A always received 
saline SC before 15-minute sessions. Group B received fentanyl SC (0.003, 0.006, 
0.012 mg/kg), Group C received low and medium doses of agonists SC, and Group D 
received spiradoline (0.3, 0.6, 1.2 mg/kg) SC during Training Sessions 1-4, rats being 
restricted to the drug-associated compartment. Rats received saline when restricted to the 
placebo-associate compartment and on test days with access to both shuttle-box 
compartments. In Phase 2 of the study, Training Session 5, Combinations of mu and kappa 
agonists were substituted in Groups B, C, and D. Dose-related preference to fentanyl and 
aversion to spiradoline occurred during Test Sessions 1-4. During Test Session 5, fentanyl 
preference in Group B was suppressed by spiradoline, rats in Group C had a saline-like 
response to combined agonists, and spiradoline aversion in Group D was attenuated by 
fentanyl. These findings suggest that combined doses of mu and kappa agonists, while 
additive for antinociception, offset the rewarding and punishing effects of each other. 
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1. Introduction 
In the last three decades much research has been conducted on behavioral effects of mu-opioid-
receptor (MOR) agonists and kappa-opioid-receptor (KOR) agonists. For example, Shippenberg and 
colleagues reported extensively on antinociceptive and motivational responses of these drug classes [1-6]. 
Generally, testing of MOR agonists in place-conditioning (PC) paradigms showed conditioned place 
preference (CPP) that was attenuated by combination with a KOR agonist. PC training with a KOR 
agonist resulted in a conditioned place aversion CPA). Concerning antinociceptive effects (ANC), both 
agonists were active when administered singly. With combined agonists, additive ANC was usually 
observed in somatic pain test models [7,8], whereas synergistic (supra-additive) ANC responses 
occurred in visceral pain tests on pairing the agonists [9,10,11] (see below for more details). 
Our laboratory initiated tests for ANC in domestic cats using visceral stimuli (colorectal distension, 
CRD), seeking reliable opioid pain relief in this species [12]. Felines react to MOR agonists with a 
manic-like excitation, compromising effective treatment [13]. We tested butorphanol (a mixed MOR, 
KOR agonist [14,15]) in cats exposed to CRD, and observed effective ANC. Butorphanol-treated 
subjects remained calm for the first hour, responding to petting with purring, as opposed to a deliriant-
type reaction to the MOR agonist oxymorphone. But, as the ANC effect began to wane, the cats 
became irritable to touch and noise, resisting being handled [16]. We also combined butorphanol and 
oxymorphone in cats, and found enhanced ANC with CRD, along with reduced side effects of both 
agonists, including the secondary irritable response to butorphanol alone. 
A class of KOR-agonist analgesics (arylacetamides, including U-50,488, enadoline, spiradoline, and 
U69593) was described by von Voigtlander and Lewis [17] as highly efficacious and selective 
analgesics acting at KOR-1 sites. We chose enadoline and spiradoline to be tested with fentanyl 
(potent and selective MOR agonist [18]) for ANC and PC studies in rats. Fentanyl and spiradoline, 
given singly, induced maximal efficacy for ANC in cold-water tail-flick (CWTF, somatic pain test 
model) and CRD. Combined agonists induced mainly additive ANC in CWTF, with reduced side 
effects of each class [7]. Rats tested with the combination in CRD (visceral pain test model) exhibited 
a synergistic ANC, with reduction of side effects of each agonist [9]. 
Pretreatment with selective MOR or KOR antagonists attenuated selectively the CWTF ANC of 
fentanyl and spiradoline, respectively, as anticipated. But pretreatment of rats with the antagonists 
against ANC in CRD did not show selective antagonisms. That is, in the visceral pain model, both 
antagonists decreased the ANC of the MOR and KOR agonists non-selectively. 
One of us (RHR)  had developed an early version of an unbiased PC procedure that included food 
appetitive responses to d-amphetamine and d-fenfluramine [19]. Fasted rats were tested in a 4-alley 
black-white x-maze. Subjects trained on d-amphetamine developed CPP, while those trained on d-
fenfluramine manifested CPA. Both drugs caused anorexia, rats mouthing but not eating pellets that 
were left in the alleys, while no pellets were observed after saline injection. 
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Briggs, as a graduate student, decided to use the x-maze to explore fentanyl and enadoline PC 
interactions as a part of her MSU dissertation research: Interactions of mu- and kappa-opioid agonists, 
which was successfully defended in 1996. Briggs observed a significant CPP in rats trained on fentanyl 
in the x-maze, which was attenuated by a low dose of enadoline. However, this enadoline dose alone, 
trained for a PC response, induced only a non-significant trend for CPA. Our enadoline supply had 
been exhausted by extensive ANC testing, and Briggs also was faced with a deadline for her thesis 
defense. Thus, she was not able to extend the x-maze PC studies at that time. 
Investigations of MOR- and KOR-agonist PC interactions have usually been prompted by searching 
for new therapies to treat MOR-agonist addiction (see Discussion). While this topic is of interest to us, 
it was not our major goal in Dr. Briggs’s x-maze study or in this shuttle-box PC work. Rather, our 
main purpose was to test the hypothesis that the aversive (dysphoric) effect of a KOR agonist could be 
suppressed by combination with a MOR agonist. This KOR-agonist aversion is the main deterrent to 
the clinical use of the KOR analgesics such as spiradoline and enadoline in humans (see Discussion). 
Thus, proof of the above hypothesis may lead to greater patient acceptance of the combined agonists, 
especially for those suffering chronic visceral pain. 
2. Experimental Methods and Materials 
2.1. Subjects and Drugs 
Male Sprague-Dawley adult rats, weighing from 220 to 270 grams at the start of the study, were 
divided into four groups of 6 rats each: A, B, C, and D. Table 1 lists the schedule of training and 
testing of drug and placebo treatments for all groups over a six-week period. 
Table 1. Schedule of training and test days, drugs and placebo sessions, for all four groups. 
Sessions Days Group A Group B Group C Group D 
Pre-training 1, 2, 4, 6 in DAC (a) 
3,5 in PAC (b) 
S (c) 
S 
S 
S 
S 
S 
S 
S 
Pre-training test 7 S S S S 
Training 
Session 1 
8, 9, 11, 13 in DAC 
 
10, 12 in PAC 
S 
 
S 
High-Dose 
Fentanyl 1 
S 
Low-Dose 
Fentanyl 1 
S 
High-Dose 
Spiradoline 1 
S 
Test Day1 14 S S S S 
Training 
Session 2 
15, 16, 18, 20 in DAC 
 
17, 19 in PAC 
S 
 
S 
Low-Dose 
Fentanyl 2  
S 
Medium-Dose 
Fentanyl 1 
S 
Low-Dose 
Spiradoline 1 
S 
Test Day 2 21 S S S S 
Training 
Session 3 
22, 23, 25, 27 in DAC 
 
24, 26 in PAC 
S 
 
S 
Medium-Dose 
Fentanyl 2 
S 
Low-Dose 
Spiradoline 2 
S 
Medium-Dose 
Spiradoline 1 
S 
Test Day 3 28 S S S S 
Training 
Session 4 
29, 30, 32, 34 in DAC 
 
31, 33 in PAC 
S 
 
S 
High-Dose 
Fentanyl 2 
S 
Medium-Dose 
Spiradoline 2 
S 
High-Dose 
Spiradoline 1 
S 
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Table 1. Cont. 
Test Day 4 35 S S S S 
Training 
Session 5 
35, 37, 39, 41 in DAC 
 
38, 40 in PAC 
S 
 
S 
HDF + LDS 
(d) 
S 
MDF + MDS 
(d) 
S 
HDS + LDSF 
(d) 
S 
Test Day 5 42 S S S S 
(a) = Subjects restricted to drug-associated compartment; (b) = Subjects restricted to placebo-
associated compartment; (c) = Saline; (d) = High-dose fentanyl plus Low-dose spiradoline; 
Medium-dose fentanyl plus Medium-dose spiradoline; High-dose spiradoline plus Low-dose 
fentanyl. 
Training and test trials were 15 min in duration. All groups received saline injections SC during the 
Pre-Training Session to establish baseline placebo responses from the results of the Pre-Training 
Test.Group A (placebo group) received only saline in all training and test trials. 
During Test Sessions 1-4 (Table 1) Group B received low-dose fentanyl, medium-dose fentanyl 
(MDF), and high-dose fentanyl to establish a dose-response pattern of conditioned place preference 
(CPP). The second high dose of fentanyl was calculated to enhance the final CPP determination. 
During Training Session 5 the combined high-dose fentanyl and low-dose spiradoline (HDF + LDS) 
tested the hypothesis that fentanyl CPP may be attenuated by addition of spiradoline. 
Group C received two dose levels of fentanyl (Training Sessions 1 and 2) and two dose levels of 
spiradoline (Training Sessions 3 and 4) to compare PC effects with those of Groups B and D, as well as 
to establish baseline values for the Group C Test Day 5, combined medium-dose fentanyl and medium-
dose spiradoline (MDF + MDS). This latter test was calculated to determine the relative strengths of 
medium doses of the combined agonists as to interaction of opposing motivational effects.  
Group D was trained to three dose levels of spiradoline (sessions 1-4) for a dose-response CPA 
pattern, the high dose repeated (HDS2) to maximize the final CPA score. Group D rats then received 
combined high-dose spiradoline and low-dose fentanyl (HDS + LDF, Test 5) to assess the capacity of 
the low dose of fentanyl to reduce the CPA score of the high dose of spiradoline.  
The drug dose levels of fentanyl, 0.003, 0.006, 0.012 mg/kg, and spiradoline, 0.3, 0.6, 1.2 mg/kg, 
were based upon previously established antinociceptive (ANC) dose-response patterns [7,9]. Fentanyl 
ANC reached peak activity at 15 min post-injection SC and began to decay at about 30 min post-
injection. Spiradoline ANC peaked near 30 min post-injection SC and began to decay about 50 min 
post-injection. Therefore, fentanyl was injected 15 min before placing a subject into the shuttle-box, 
and spiradoline was injected 30 min prior to placement.  
Fentanyl citrate was purchased from Elkins-Sims, Inc. (Cherry-Hill, NJ, USA). Spiradoline was 
generously supplied by P. L. von Voigtlander (Upjohn Co., Kalamazoo, MI, USA). The drugs were 
dissolved in normal saline. The rats and procedures were approved for this study, per NIH standards, 
by the Animal Use and Care Committee, Michigan State University. 
2.1. Conditioning Apparatus, Training and Testing Parameters 
Two shuttle-boxes were constructed with two compartments each, 35 cm long by 13 cm wide by 13 cm 
high. The compartments were joined at the narrow walls on one side, in which 7 cm diameter circles 
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analyzed with a computer-based program designed for complex matrices. This was the Tukey-Kramer 
Test, GraphPad Instat version 3.05, GraphPad Software, Inc., calculating both within-group and 
between groups differences of pairs of values (http://www.graphpad.com). 
The number of shuttles performed by each rat in each session were also determined from the timer-
event recorder tapes. These scores were analyzed for statistical differences using the Student 
Neumann-Kuels’ test. The shuttle responses, then, provided a convenient method of comparing levels 
of locomotor activity (LMA) for each rat and treatment. 
3. Results and Discussion 
3.1. Results 
The place preference of fentanyl and place aversion of spiradoline, and their interactions, yielded a 
highly significant difference by an overall treatment of all the data, p < 0.0001. The program printout 
also supplied means +/- standard errors (SEMs) of scores for each group. The Tukey-Kramer Multiple 
Comparisons Test analyzed all possible pairs of scores for each group to determine within-group and 
between-groups differences for all Table 1 test scores. These results are graphed in Figure 2. 
Figure 2. Place-Conditioning Scores (Means +/− SEMs) of Rat Groups Treated with 
Fentanyl, Spiradoline, and Combinations for the Sequence of the Six Tests Listed in Table 
1. Statistical comparisons of group pairs of these scores were done using the Tukey-
Kramer Program (see Methods). Scores marked with asterisks are significantly different 
from saline scores by p < 0.001. Scores without asterisks do not differ from saline scores. 
The symbol # indicates Test 5 scores differ from Test 4 scores for Groups B, C, and D; B 
and D by p < 0.001, and C by p < 0.01. The statistical differences of the remaining critical 
pairs of scores are presented in Table 2. Abbreviations: DAC = Drug-Associated 
Compartment; PT = Pre-Training Tests with Saline. HDF1 = High-Dose Fentanyl 1, 
LDS2 = Low-Dose Spiradoline 2, HDF + LDS = combined fentanyl and spiradoline, etc.  
 
The analysis indicated significant differences at p < 0.001 for 127 pairs of the total of 171 pairs 
analyzed. Of the remaining 44 pairs, 3 differed by p < 0.01, 11 differed by p < 0.05, and 30 were not 
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significantly different. The numerical means +/− SEMs of scores and the more critical significant 
differences are listed in Table 2. 
Table 2. Place-Conditioning Scores: І. Means +/− SEMs derived from comparing group 
Saline values with Group Fentanyl, Spiradoline, or combination values for Sequences of 
Saline and drug training as listed in Table1 , using the Tukey-Kramer program of statistical 
analysis. ІІ. Statistical comparisons of drug/drug pairs for both Within-Group comparisons 
or Between-Groups comparisons of most critical pairs. 
І. Group Group A Group B Group C Group D 
Pre-training 
Day 7: 
Saline  
49.53+/−1.00 (a) 
Saline 
49.96+/−1.64 
Saline 
50.05+/−1.99 
Saline 
50.27+/−1.45 
Test 1  
Day 14:  
Saline  
 
High-Dose 
Fentanyl 2 
74.07+/−1.17 
Low-Dose 
Fentanyl 1 
60.93+/−0.72 
High-Dose 
Spiradoline 1 
34.67+/−0.87 
Test 2  
Day 21:  
Saline  
 
Low-Dose 
Fentanyl 2 
62.63+/−0.98 
Medium-Dose 
Fentanyl 1 
71.38+/−1.49 
Low-Dose 
Spiradoline 1 
45.28+/−1.15 
Test 3  
Day 28: 
Saline  
 
Medium-Dose 
Fentanyl 2 
74.32+/−1.91 
Low-Dose 
Spiradoline 2 
44.08+/−0.77 
Medium-Dose 
Spiradoline 1 
39.58+/−0.60 
Test 4  
Day 35: 
Saline  
 
High-Dose 
Fentanyl 2 
79.67+/−1.69 
Medium-Dose 
Spiradoline 2 
38.37+/−0.97 
High-Dose 
Spiradoline 2 
29.10+/−0.87 
Test 5  
Day 42: 
Saline  
 
High-Dose 
Fentanyl plus 
Low-Dose 
Spiradoline 
68.28+/−1.23 
Medium-Dose 
Fentanyl plus 
Medium-Dose 
Spiradoline 
45.56+/−1.18 
High-Dose 
Spiradoline 
plus Low-
Dose Fentanyl 
37.38+/−1.01 
ІІ. Within-Group comparisons of drug/drug pairs of scores: Group B pairs differ by p < 0.001, except 
for HDF1 vs. MDF2 (n.s.). Group C pairs differ by p < 0.001, excepting MDS2 vs. MDF + MDF 
(p < 0.05), and LDS2 vs. MDF + MDS (n.s.). Group D differ by p < 0.001, excepting HDS2 vs. 
MDS1 and HDS1 vs. HDS2 (p < 0.01), LDS1 vs. MDS1 and HDS2 vs. HDS + LDF (p < 0.05), and 
HDS1 vs. HDF + LDF and MDS1 vs. HDS + LDF (n.s.). 
Between-Group comparisons of drug/drug pairs of scores: Group B vs. Group C pairs differ by 
p < 0.001, excepting HDF2 vs. MDF1 (p < 0.05), and HDF1 vs. MDF1, LDF2, and MDF2 vs. 
MDF1 (n.s.). Group B vs. Group D pairs differ by p < 0.001. Group C vs. Group D pairs differ by 
p < 0.001, except for LDS2 vs. MDS1, LDS1 vs. MDS2, MDS2 vs. HDS1, and MDF + MDS vs. 
HDS + LDF (p < 0.05), and LDS1 vs, LDS2, MDS2 vs. HDS + LDF, MDS1 vs. MDS2, and LDS1 
vs. MDF + MDS (n.s.). 
Saline pairs were all non-significant (n.s.). Within-group comparisons derive from vertical 
columns, between-group comparisons from horizontal or lateral columns of І. Abbreviation codes 
for ІІ: LDF = Low-Dose Fentanyl; MDF = Medium-Dose Fentanyl; HDF = High-Dose Fentanyl; 
LDS = Low-Dose Spiradoline; MDS = Medium-Dose Spiradoline; HDS = High-Dose Spiradoline; etc. 
Examining within-group comparisons, we established a dose-related preference to fentanyl in Tests 
2-4 in Group B, though there was no significant difference between High-Dose Fentanyl 1 and 
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Medium-Dose Fentanyl 2. Comparing Group B’s High-Dose Fentanyl 2 vs. High-Dose Fentanyl + 
Low-Dose Spiradoline resulted in a difference of p < 0.001. Dose-related preference was also evident 
to spiradoline in Tests 2-4 for Group D, though truncated, since D’s Low-Dose Spiradoline 1 was not 
different than that group’s Saline score. High-Dose Spiradoline 2 vs. High-Dose Spiradoline + Low-
Dose Fentanyl differed by p < 0.001. 
In Group C, Tests 1-4, there were significant differences for Low-Dose Fentanyl 1 vs. Medium-Dose 
Fentanyl 1 preference and for Low-Dose Spiradoline 2 vs. Medium-Dose Spiradoline 2 aversion, both at 
p < 0.001. Group C’s Medium-Dose Spiradoline 2 vs. Medium-Dose Fentanyl + Medium-Dose 
Spiradoline, Test 4 vs. Test 5, yielded a significance of p < 0.01. But Test 5 score vs. C’s Saline score 
was not significantly different. On pairing Group C’s fentanyl scores with that Group’s spiradoline 
scores, the comparisons differed by p < 0.001, as expected.  
To reiterate, comparing Test 4 vs. Test 5 scores in B or C, within-group analyses, a high preference 
by fentanyl in B was much reduced when paired with the low dose of spiradoline, and a medium level 
of aversion by spiradoline in C was reversed when paired with the medium dose of fentanyl. Group 
C’s Test 5 score vs. Saline did not differ. 
Group D’s within-group Test 4 vs. Test 5 demonstrated that a strong aversive conditioning to 
spiradoline could be offset by combination with fentanyl, even at a low dose of the MOR agonist. 
Consider that High-Dose Spiradoline 2 vs. Group D’s Saline differed by p < 0.001, whereas High-
Dose Spiradoline 2 vs. High-Dose Spiradoline + Low-Dose Fentanyl differed by only p < 0.05.  
Between-groups comparisons, less critical than within-group pairings, still produced results of 
interest. Pairs of Group B vs. Group C scores differed by p < 0.001, except for non-significance with 
High-Dose Fentanyl 1 vs. Medium-Dose Fentanyl 1, Low-Dose Fentanyl 1 vs. Low-Dose Fentanyl 2, 
Medium-Dose Fentanyl 1 vs. Medium-Dose Fentanyl 2, and Medium-Dose Fentanyl 1 vs. High-Dose 
Fentanyl + Low-Dose Spiradoline. All Group B vs. Group D between-groups scores differed by  
p < 0.001, as anticipated. Fourteen pairs of Group C vs. Group D comparisons differed by p < 0.001, 
most being fentanyl scores vs. spiradoline scores. Two pairs, Low-Dose Spiradoline 2 vs. Medium-
Dose Spiradoline 1 and Medium-Dose Fentanyl + Medium-Dose Spiradoline vs. High-Dose 
Spiradoline + Low-Dose Fentanyl differed by p < 0.05. The last four pairs, Low-Dose Spiradoline 1 
vs. Low-Dose Spiradoline 2, Medium-Dose Spiradoline 1 vs. Medium-Dose Spiradoline 2, Medium-
Dose Spiradoline 2 vs. High-Dose Spiradoline + Low-Dose Fentanyl, and Medium-Dose Spiradoline 2 
vs. Medium-Dose Fentanyl + Medium-Dose Spiradoline, did not differ significantly.  
Analyzing pairs of scores that included Saline understandably produced many that were highly 
significant as well as non-significant. Group A, receiving only saline injections throughout the study, 
registered values not significantly from each other or from Saline scores of the other groups. Of the 
drug/Saline combinations, only three failed to display significant differences: LDS1 vs. any group’s 
Saline score, LDS2 vs. any group’s Saline score, and MDF + MDS vs. any group’s Saline score.  
As indicated above in Experimental Methods and Materials the number of shuttles made by each 
rat in every session was used as an index of the subject’s level of locomotor activity (LMA). This 
measure was calculated to determine any drug-induced effect on LMA that might have compromised 
the integrity of the PC data. Each group’s LMA scores, means +/− SEMs, and levels of significant 
differences, are depicted in Figure 3. 
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The analyses of the LMA scores indicate that Low-Dose Fentanyl 2, Group B, differed by p < 0.05 
from the High-Dose Fentanyl 1, High-Dose Fentanyl 2, High-Dose Spiradoline 1, and High-Dose 
Fentanyl + Low-Dose Spiradoline LMA scores, while the High-Dose Spiradoline 2 LMA score 
differed by p < 0.01. Also, Low-Dose fentanyl 1 (LDF1) LMA score of Group C differed from the 
HDS2 LMA score, Group D, by p < 0.05. 
Figure 3. Locomotor Activity (LMA) Scores (Means +/− SEMs) of Rat Groups Treated 
with Fentanyl, Spiradoline, and Combinations for the Sequence of the Six Tests Listed in 
Table 1. Statistical comparisons of group pairs of these scores (number of shuttles per 
group per session) were done by Student Neuman Keuls’ Test. The Low-Dose Fentanyl 2 
score, Group B (*), differed significantly from High-Dose Fentanyl 1, High-Dose Fentanyl 2, 
High-Dose Spiradoline 1, and High-Dose Fentanyl + Low-Dose Spiradoline by p < 0.05, and 
from High-Dose Spiradoline 2 by p < 0.01. The Low-Dose Fentanyl 1 score, Group C (#), 
differed significantly from High-Dose Spiradoline 2 by p < 0.05. Abbreviations: 
PT = Pre-Training Tests with Saline. 
 
3.2. Discussion 
In the Introduction we reviewed our studies of mu-opioid-receptor (MOR) agonist and kappa-
opioid-receptor (KOR) agonist antinociceptions (ANC) in the colorectal distension test (CRD), alone 
or combined, in cats and rats [7,9,10,12,16]. The purpose for that review was to describe incidental 
observations of drug-induced behavioral effects that were observed during those experiments. Cats 
reacted to a MOR agonist alone (oxymorphone) with agitation, excitement, and disorientation. 
Butorphanol (mixed MOR, KOR agonist [14,15]), given in combination with oxymorphone, calmed 
the subjects and enhanced the ANC over each single drug effect alone. Cats remained quiet and 
impassive over the first hour or so after butorphanol injection. During the next hour, however, as the 
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ANC began to wane, a second phase set in, marked by irritability and hypersensitivity to stimuli. This 
secondary pattern appears to be the emergence of the KOR aversive component of the drug as the 
MOR component decayed [15]. 
We also tested butorphanol in dogs [20] for ANC, using the CRD visceral pain model. Behavioral 
reactions to the drug in dogs were similar to those in cats, excepting mania, while combined MOR, 
KOR agonists suppressed the KOR-agonist irritability and hypersensitivity. 
The place conditioning (PC) apparatus used in this study, with two compartments, is unusual but 
not unique. It differs from the x-maze used by Briggs in her dissertation research (described above) 
and from most other multi-compartment PC mazes. Shippenberg et al. [2,3] also used a black-white 
shuttle-box (see below), and Morales et al. [21] described a two-compartment PC device as superior to 
multi-compartment designs for developing place-conditioning responses for opioid drugs. We 
determined the shuttle-box apparatus to be more efficient for developing PC patterns of MOR and 
KOR agonists than was the x-maze. 
The shuttle-box procedure included an automated technique for recording the subject’s PC and 
locomotor activity (LMA) behaviors. The PC apparatus used by Morales et al. [21] also included an 
automated recording device. Automated recording obviates the need for an observer constantly 
hovering over the maze, promoting distractions in the subjects as well as subjective errors in judging 
the subject’s responses. Use of two compartments also did not involve neutral transitional areas, where 
subjects may dwell and dilute the percent of time they spend in designated drug or placebo areas, 
making PC training less efficient.  
A further advantage of the shuttle box format was the ability to measure number of shuttles per 
session, taken as a measure of LMA. Since LMA responses (Figure 2) were not at all correlated with 
PC behavior (Figure 1), we were assured that the PC patterns were not confounded by drug-induced 
LMA effects. 
The data in Figure 2 show that some comparisons of drug-pair scores that were not significantly 
different involved identical drug doses (example: Low-Dose Spiradoline1 vs. Low-Dose Spiradoline 2) 
or those differing by one dose level that appeared to have been skewed by the prior PC training 
sequence (example: High-Dose Fentanyl 1 vs. Medium-Dose Fentanyl 2). The response of Group C in 
test 5 to Medium-Dose Fentanyl + Medium-Dose Spiradoline vs. the Test 4 Medium-Dose Spiradoline 
2 showed a prominent reduction in the level of spiradoline aversion by adding the medium dose  
of fentanyl.  
The agonists appeared to act reciprocally, or nearly so, in offsetting one-another’s opposing 
motivational effects. This relationship is also supported by Group B and Group D Test 4 and Test 5 
results: a low dose of spiradoline reduced appreciably the preference of a third high dose of fentanyl 
(B) and a low dose of fentanyl suppressed to a large extent the aversion of a third high dose of 
spiradoline (C) (Table 2). 
The result that preference occurring with a MOR agonist (fentanyl) was attenuated by a KOR 
agonist (spiradoline) is certainly not an original observation. This pattern has been reported by a 
number of investigators [6,22-25]. Several of these authors proposed that this effect may lead to a new 
therapeutic approach for treatment of MOR-agonist addictions. However, the potential of combining 
MOR and KOR agonists to suppress the dysphoric effect of KOR agonists, making them more 
acceptable to patients, has received little recognition. The main obstacle to the clinical application of 
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the KOR-1 agonists spiradoline, enadoline, and U69593 as analgesics has been this prominent 
dysphoria [2,14,17]. 
Funada et al. [23] reported in mice that U-50,488 (KOR-1 agonist) and E-2078 (dynorphin, 
endogenous KOR-agonist analogue) developed conditioned place aversion (CPA) in higher doses. 
Lower (non-aversive) doses still attenuated conditioned place preference (CPP) caused by morphine. 
These KOR-agonist-induced effects were abolished after pretreatment with nor-binaltorphimine (nor-
BNI, KOR-1 antagonist) [26]. Our PC results testing the low dose of spiradoline (non-aversive, see 
Figure 2) combined with the high dose of fentanyl also showed a prominent decrease in the MOR 
agonist’s CPP. Thus, KOR-agonist suppression of MOR-agonist CPP appears to involve more than a 
simple cancellation of opposing CPP and CPA states [4]. 
Shippenberg et al. [3], referred to above, subjected naïve rats to hind-limb inflammation, injecting 
Freund’s adjuvant (FA) to produce marked morphine-induced CPP. Rats receiving 7 days of FA 
exhibited CPP of the same magnitude. Naïve rats receiving U69593 (KOR-1 agonist) manifested CPA.  
However, rats receiving 7 days of FA failed to develop CPA after U69593 PC training, possibly by 
activation of an endogenous MOR agonist. If so, their results support our hypothesis (see pg. 3) that 
opposing rewarding and aversive motivational states interact to cancel each other.  
Shippenberg et al. also produced CPP with fentanyl and morphine, developing tolerance to the CPP 
after 4 days of non-contingent morphine [2]. Non-contingent U69593 also caused tolerance to 
U69593-developed CPA. No cross-tolerance was seen between the MOR- and KOR-agonists. The 
authors discussed the potential use of KOR agonists as analgesics in chronic pain states, since U69593 
CPA was nullified by 7-day FA pretreatment. They suggested that the abolition of this KOR-induced 
CPA related to a specific alteration in motivational effects of U69593. These results support our 
proposal that combined MOR and KOR agonists may offer superior pain relief in states of chronic 
visceral pain [9]. 
Narita et al. [27] noted that patients suffering from cancer pain appeared to develop less than 
normal psychological dependence upon morphine. They tested for CPP of morphine in control rats and 
those exposed to inflammation by chronic formalin injections. The inflamed subjects exhibited a 
suppression of CPP development which was reversed by the KOR-1 antagonist nor-BNI. Their results 
are further support for our hypothesis that opposing opioid motivational states interact to reciprocally 
reduce each other.  
Narita et al. also reduced the dopamine activity in nucleus accumbens by morphine microinjections 
in control rats when provoking inflammation in the experimental group. This reduction, in turn, was 
reversed by dopamine A antibody put into nucleus accumbens. They proposed a suppression of 
morphine reward mechanisms by formalin-induced activation of endogenous KOR agonist systems. 
Yamamoto et al. [28] found that tolerance development to repeated morphine ANC responses in 
rats was reversed by U-50,488. Since inhibitory KORs are known to exist in a brain-stem nucleus 
involving MOR tolerance mechanisms, their activation may have suppressed development of morphine 
tolerance and maintained ANC. 
He and Lee [29] described the restoration of morphine ANC in morphine-tolerant mice by the 
administration of dynorphin A-(2-17). They suggested that the tolerance depended upon simultaneous 
activation of MOR sites in the brain and spinal cord, since ANC from intracerebroventricular (i.c.v.) 
morphine or intrathecal (i.t.) morphine was resistant to tolerance, i.e., MOR/KOR agonist interactions. 
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Combined i.c.v. and i.t. morphine in naïve animals induced marked ANC synergism. Similar data 
and concepts were presented by Miatkowski et al. [11] in a series of ANC effects of MOR and KOR 
agonists in rats. The results of both these groups support the hypothesis that systemic KOR-agonist 
activity reverses systemic MOR-agonist tolerance. 
Negus et al. [8] performed a recent study analyzing ANC and rewarding/aversive interactions of 
fentanyl and U69593 in rhesus monkeys, with elements in common with our studies. They described a 
dose-related ANC for both agonists using warm-water tail-withdrawal (somatic pain model). 
Combined agonists produced additive ANC, as was the case for the agonists interacting in the cold-
water tail-flick in rats reported by our group [7]. It differed from the synergistic ANC observed with 
the combined drugs using colorectal distension in rats (CRD, a visceral pain model [9]). These 
differences appear to relate to distinct central nervous system loci sub-serving the somatic vs. visceral 
pain mechanisms (this theme will be expanded below). 
The Negus et al. article also included interactions of fentanyl and U69593 in schedule-controlled 
responding for food presentation and in a self-administration fixed-ratio (FR) paradigm. The agonists 
singly produced rate-decreasing effects in the food presentation, and the combination yielded sub-
additive effects. Fentanyl, but not U69593, maintained self-administration responding when given singly.  
Adding U69593 to fentanyl caused a proportion-dependent decrease in self-administration rates, as 
well as an increased sensitivity with increasing FR rates (FR strain). It was suggested that the 
combined agonists reduced abuse liability without compromising the ANC actions. The authors 
cautioned, however, that the decrease in self-administration rates could have been induced by non-
motivational schedule-controlled effects of the drug combination. It was unclear whether or not 
U69593 aversion was indicated by a reduced self-administration rate below that following placebo 
(saline) injection. 
That very complex PC interactions of MOR and KOR agonists occur at various brain loci is 
apparent from a study by Sante et al. [30]. They microinjected morphine and U-50,488 into the dorsal 
periaqueductal gray matter of rats tested in a 4-chambered PC procedure. Both agonists induced a 
CPA. Microinjection of a MOR antagonist (CTOP) did not block these effects, but pretreatment with 
nor-BNI did. CTOP alone induced CPA, while nor-BNI alone did not.  
We observed paradoxical effects of MOR and KOR-agonists and antagonists on ANC in rats tested 
in CRD [9]. Spiradoline ANC alone was antagonized more by the MOR-specific antagonist beta-
funaltrexamine (beta-FNA) than by the KOR-specific antagonist nor-BNI, and the opposite was true 
for fentanyl. The synergistic ANC of combined agonists was reduced to 50% after beta-FNA and to 
25% after nor-BNI. 
Fentanyl is a selective MOR agonist and spiradoline is a selective KOR-1 agonist [7]. It is unlikely, 
then, that any portion of their PC interactions relates to direct effects on the same neural opioid receptors. 
Neurobiological correlates of opioid-agonist-induced CPP have been postulated to involve dopaminergic 
and MORs in brain ventral striatum and other mesolimbic areas associated with development of 
preference. Aversive responses are thought to entail dynorphin (endogenous kappa opioid) receptors and 
cholinergic receptors in the extended amygdala and other mesocortical sites [31,32]. 
Evidence that the motivational interactions of MOR and KOR agonists as described above may 
apply to humans was furnished by Preston and Bigelow [33]. They induced MOR agonist activity 
(hydromorphone) and KOR plus MOR activity (pentazocine) in human volunteers. A 25 mg dose of 
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naltrexone (non-selective opioid antagonist) blocked both MOR- and KOR-agonist effects. However, a 
12.5 mg dose of naltrexone decreased the MOR-agonist effect of pentazocine and uncovered greater 
KOR-agonist activity of pentazocine (dysphoria, psychotomimetic influences). Thus, simultaneous 
MOR and KOR agonist effects can result in suppression of KOR-agonist aversive side effects in man, 
in agreement with the results of the present study in rats and in other studies [3, 4].  
4. Conclusions 
The above-presented data suggest several types of MOR- and KOR-agonist interactions: 
(1) Dose-related place preference to fentanyl and dose-related place aversion to spiradoline were 
observed in the shuttle-box test model. These same dose ranges of the agonists were previously shown 
to induce dose-related additive [7] and synergistic [9] antinociception in Cold-Water Tail-Flick and 
colorectal distension, respectively. 
(2) Combined agonists appeared to result in a mutual antagonism of MOR-agonist preference and 
KOR-agonist aversion, offsetting one-another. Proposed neural mechanisms for these opposing 
motivational response patterns include neuronal components in brainstem nuclei, mesolimbic and 
mesocortical circuits, and frontal-brain extended amygdalar complex, competing to express euphoric 
or dysphoric states ofmind [3,4,5,22,23,27,29,30,31,32,33]. 
(3) The neural substrate for colorectal distension antinociceptive interactions of the agonists 
appears to differ from the above, involving neural spinal/supraspinal chains containing interspersed 
MOR and KOR units to support a synergistic antinociception [34,35,37,38,39]. 
(4) The reciprocal suppressions of MOR-agonist preference and KOR agonist aversion with 
combined agonists suggests a clinical potential for improved control of pain in human patients, and, in 
particular, chronic visceral pain syndromes. Combining the agents in this manner should reduce the 
levels of adverse side effects, including KOR agonist dysphoria, and the risk of MOR-agonist 
addiction, tolerance, dependence, and hyperalgesia. 
In the latter part of the last century the conventional wisdom concerning attempts to combine opioid 
drugs for greater and safer pain relief was that the concept had no merit [40,41,42]. This conclusion 
was apparently based mainly upon results of experimental somatic pain studies and agonist-antagonist 
characteristics of the earlier kappa-opioid agonist’s profiles (pentazocine, nalbuphine). We propose 
that the data presented above indicates that this judgment was premature. 
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